COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT05311813


Column Value
Trial registration number NCT05311813
Full text link
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

https://clinicaltrials.gov/show/NCT05311813

First author
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Raghda R.S. Hussein

Contact
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Not reported

Registration date
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

2022-04-05

Recruitment status
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Open label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

single-center

Study aim
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

inclusion criteria: laboratory confirmed covid-19 infection by pcr test within 7 days prior to admission or during admission to hospital, ct or radiographic findings of pneumonia. clinically suspected infection by symptoms like loss of smell and taste. no medical history that may interfere with treatment or with this clinical trial.

Exclusion criteria
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

patient who had allergy or contraindication to hcq, pregnant and lactating females, and patients with immune diseases, cardiac problem, had history of acute kidney injury or who received multiple cycles of anticoagulants were excluded from the study. written informed consent was obtained from each participant. all study risks and benefits were thoroughly explained to patients' prior participation

Number of arms
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

4

Funding
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Beni-Suef University

Inclusion age min
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

75

Countries
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Egypt

Type of patients
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Moderate/severe/critical disease at enrollment

Severity scale
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

5: Moderate/severe/critical disease at enrollment

Total sample size
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

200

primary outcome
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Assessment of efficacy

Notes
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

Not reported

Arms
Last imported at : April 6, 2022, 9 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "nan", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "nan", "treatment_id": 463, "treatment_name": "Enoxaparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 607, "treatment_name": "Hydroxychloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2429, "treatment_name": "Enoxaparin+hydroxychloroquine", "treatment_type": "Coagulation modifiers+antimalarials", "pharmacological_treatment": "Pharmacological treatment"}]